J. Goldman & Co LP Invests $5.02 Million in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

J. Goldman & Co LP acquired a new position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 296,045 shares of the biotechnology company's stock, valued at approximately $5,024,000. J. Goldman & Co LP owned about 1.09% of Arcturus Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Wellington Management Group LLP raised its stake in shares of Arcturus Therapeutics by 0.8% in the 4th quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company's stock valued at $1,647,000 after buying an additional 742 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Arcturus Therapeutics by 5.0% during the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock worth $316,000 after acquiring an additional 883 shares during the last quarter. Virtus ETF Advisers LLC grew its holdings in Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock worth $69,000 after acquiring an additional 1,132 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Arcturus Therapeutics by 7.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company's stock worth $323,000 after acquiring an additional 1,279 shares during the last quarter. Finally, Brevan Howard Capital Management LP boosted its stake in shares of Arcturus Therapeutics by 13.7% in the 4th quarter. Brevan Howard Capital Management LP now owns 12,305 shares of the biotechnology company's stock valued at $209,000 after purchasing an additional 1,486 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Price Performance

ARCT stock traded up $0.80 during midday trading on Thursday, reaching $11.64. 376,253 shares of the company were exchanged, compared to its average volume of 450,790. The business has a 50-day moving average price of $11.69 and a two-hundred day moving average price of $15.35. Arcturus Therapeutics Holdings Inc. has a one year low of $8.04 and a one year high of $45.00. The firm has a market capitalization of $315.69 million, a price-to-earnings ratio of -5.24 and a beta of 2.36.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($1.58) by $1.06. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $29.38 million during the quarter, compared to the consensus estimate of $25.64 million. As a group, analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ARCT. Citigroup reaffirmed a "buy" rating on shares of Arcturus Therapeutics in a research note on Tuesday. HC Wainwright restated a "buy" rating and set a $60.00 target price on shares of Arcturus Therapeutics in a report on Thursday, April 10th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. Canaccord Genuity Group decreased their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a research note on Tuesday. Finally, BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the company a "buy" rating in a research note on Monday, March 10th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $57.80.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.